Skip to main content

Catalyst Calendar

Scope

Tue, Aug 25, 2026

1 updates
PRTC
7:05 AM

PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress

RNS Number: 0041S PureTech Health PLC 25 August 2026 25 August 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress Presentations will highlight Celea's differentiated approach to

Presentation / Abstract • Phase 1ERS oral presentation Mon, Sep 7, 2026, 11:05 AM CESTpuretechhealth.com

Mon, Jul 13, 2026

1 updates
PRTC
2:00 AM

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

RNS Number: 0542M PureTech Health PLC 13 July 2026 13 July 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) SURPASS-IPF is the

Trial Start • Phase 3Trial initiation Mon, Jul 13, 2026puretechhealth.com

Thu, Jul 2, 2026

2 updates
PRTC
2:00 AM

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

RNS Number: 7005K PureTech Health PLC 02 July 2026 2 July 2026 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION PureTech Health plc PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to

puretechhealth.com

Wed, Jun 10, 2026

1 updates
PRTC
12:38 PM

Results of Annual General Meeting

RNS Number: 8399H PureTech Health PLC 10 June 2026 10 June 2026 PureTech Health plc Results of Annual General Meeting The Annual General Meeting of PureTech Health plc (LSE: PRTC) (" PureTech " or the "Company") was held at 11 a.m. EDT / 4 p.m. BST on Wednesday, June 10, 2026.

puretechhealth.com

Tue, Jun 9, 2026

1 updates
PRTC
2:00 AM

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

RNS Number: 5025H PureTech Health PLC 09 June 2026 9 June 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) (" PureTech "

Trial Results • Phase 1Results event Mon, Jun 8, 2026puretechhealth.com